<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03395639</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-C-U313</org_study_id>
    <secondary_id>2017-000475-90</secondary_id>
    <nct_id>NCT03395639</nct_id>
  </id_info>
  <brief_title>Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease</brief_title>
  <official_title>An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A committee will judge the safety and effectiveness of edoxaban and the regular treatment
      (standard of care).

      All children in the study will receive free treatment. They will have a 2 in 3 chance to
      receive edoxaban, and a 1 in 3 chance to receive the standard of care for preventing blood
      clots.

      The study will find out if edoxaban is safer and more effective than the standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare the safety of edoxaban with the standard of care (SOC) in
      pediatric subjects with cardiac diseases at risk of thromboembolic complications who need
      primary or secondary anticoagulant prophylaxis with regard to the combination of major and
      clinically relevant non-major (CRNM) bleeding per International Society on Thrombosis and
      Haemostasis [ISTH] definition.

      The key secondary objective is to compare the efficacy of edoxaban against SOC with regard to
      the development of symptomatic thromboembolic events (TE) in the systemic arterial or venous
      pathways including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac
      thrombus and myocardial infarction (MI), and asymptomatic intracardiac thrombus identified by
      cardiac imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with combined bleeding events within the main treatment period</measure>
    <time_frame>within 4 months (3-month Main Treatment Period + 30-day follow-up)</time_frame>
    <description>Combined bleeding events include major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring within the main treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with combined bleeding events during the entire trial (from first to the last dose plus 30 days)</measure>
    <time_frame>within 13 months (3-month Main Treatment Period + 9-month Extension Period + 30-day follow-up)</time_frame>
    <description>Combined bleeding events include major and clinically-relevant non-major (CRNM) bleeding events per International Society on Thrombosis and Haemostasis (ISTH) definition occurring on treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways</measure>
    <time_frame>within 4 months</time_frame>
    <description>Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus and myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways</measure>
    <time_frame>within 13 months</time_frame>
    <description>Symptomatic thromboembolic events (TE) in the systemic arterial or venous pathways include deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, intracardiac thrombus and myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who died as a result of TE between randomization and the date of the last dose of study drug plus 30 days</measure>
    <time_frame>within 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who died as a result of any cause between randomization and the date of the last dose of study drug plus 30 days</measure>
    <time_frame>within 13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Edoxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two out of three participants will be randomized for treatment with edoxaban solution or tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One out of three participants will be randomized for treatment with the institution's SOC regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Edoxaban 15 mg or 30 mg tablets for participants 12 to &lt;18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration</description>
    <arm_group_label>Edoxaban</arm_group_label>
    <other_name>Lixiana</other_name>
    <other_name>Savaysa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <description>Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <other_name>Warfarin/heparin</other_name>
    <other_name>Enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a child with cardiac disease who is at risk for thromboembolic complications and
             requires at least 3 months antithrombotic anticoagulant prophylaxis

        Either one of the following:

          1. a child with cardiac disease who has a history of cardiac shunt occlusion/thrombosis,
             with shunt still in place (secondary prevention).

             OR

          2. a child with cardiac disease who requires (including those already taking, and those
             not yet taking) anticoagulation for primary prevention of TE.

        Cardiac conditions known to significantly increase the risk of thrombosis (hence,
        indications for primary TE prevention) are defined in Antithrombotic Therapy and Prevention
        of Thrombosis. Some examples of cardiac conditions at risk of thrombosis are Fontan
        surgery, heart failure, Kawasaki disease, and Blalock-Taussig and Glenn surgery.

          -  Is a male or female child between 1 and &lt;18 years of age (children between 38 weeks
             gestational age and 1 year of age will be included in the study, however, only after
             the safety and efficacy data of 50 subjects between 1 and &lt;18 years of age in the
             edoxaban arm have been evaluated at the end of the 3-month treatment period)

          -  Has parent(s)/legal guardian(s) or legally acceptable representative who is informed
             and provides signed consent for the child, to participate in the study with edoxaban
             treatment. Pediatric participants with appropriate intellectual maturity will be
             required to sign an assent form in addition to the signed informed consent from the
             parent(s)/legal guardian(s) or any legally acceptable representative.

          -  If a female subject of childbearing potential, tests negative for pregnancy at
             Screening and consents to avoid becoming pregnant by using a locally approved
             contraception method throughout the study

        Exclusion Criteria:

          -  Has evidence of symptomatic venous or arterial thrombosis and/or asymptomatic
             intracardiac thrombosis confirmed by a transthoracic echocardiogram during study
             screening period

          -  Has mechanical heart valve(s)

          -  Has active bleeding or high risk of bleeding contraindicating treatment with
             anticoagulant

          -  Takes antithrombotic therapy (other than low-dose aspirin) that is not
             protocol-related

          -  Administration of rifampin is prohibited during the study and subjects on concomitant
             use of rifampin are excluded

          -  Has any hepatic disease associated with coagulopathy leading to a clinically relevant
             bleeding risk

          -  Has estimated glomerular filtration rate (eGFR) &lt;30% of normal for age and size

          -  Has stage 2 hypertension defined as blood pressure systolic and/or diastolic confirmed
             &gt;99th percentile plus 5 mmHg

          -  Has thrombocytopenia or life expectancy less than three months

          -  Has had Fontan procedure with a history of or signs/symptoms suggestive of
             protein-losing enteropathy

          -  Is pregnant or breastfeeding

          -  Has a contraindication to the use of heparin and/or vitamin K antagonist (VKA)

          -  Has any condition that, as judged by the Investigator, would place the participant at
             increased risk of harm if he/she participated in the study, including contraindicated
             medications identified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>908-992-6400</phone>
    <email>CTRinfo@dsi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>205-638-2018</phone>
      <email>khock@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardon Childrens Medical Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse Administrator</last_name>
      <phone>480-412-5561</phone>
      <email>Stephanie.Blythe@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center (ECG)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>424-315-2297</phone>
      <email>Jennifer.chang3@cshs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California-San Francisco Department of Pediatrics - Hematology/Oncology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-514-1489</phone>
      <email>Victoria.Vanderpoel@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>352-294-8714</phone>
      <email>dalylc@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-1549</phone>
      <email>kvanthof@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>312-563-2134</phone>
      <email>Sawsan_M_Awad@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>504-842-5200</phone>
      <email>kamill.deltoro@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novant Health Heart and Vascular institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>East Carolina Heart Institute @ ECU</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>252-744-2161</phone>
      <email>stanleyt18@ecu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-716-0308</phone>
      <email>snorona@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OU Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>405-271-4411</phone>
      <email>Charles-Sperrazza@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>434-243-0910</phone>
      <email>crb3y@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-987-5914</phone>
      <email>Courtney.dethlefs@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Med Campus IV</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+43 576808424817</phone>
      <email>Andreas.Tulzer@kepleruniklinikum.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76054</phone_ext>
      <email>hamiltonko@hhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>514-315-4931</phone>
      <phone_ext>2152</phone_ext>
      <email>nagib.dahdah.hsj@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre/Glen Site/Montreal Children's Hospital</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>514-412-4400</phone>
      <phone_ext>24445</phone_ext>
      <email>christine.sabapathy@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+385 12367591</phone>
      <email>dorotea.bartonicek@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zagazig University Hospital</name>
      <address>
        <city>Zagazig</city>
        <state>Al Sharkeya</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+20 35840476</phone>
      <email>m_a_badr2005@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexandria Clinical Research Center, Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+20 1227392947</phone>
      <email>drhoda@doctor.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kasr Elainy School of Medicine, Abo Elreesh Hospital (Japanese Hospital), Ali Basha Ibrahim ST Faculty of Medicine Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+20 1222152161</phone>
      <email>dr.hala_hamza@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+20 1000864343</phone>
      <email>elalfym@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suez Canal University Hospital</name>
      <address>
        <city>Ismailia</city>
        <zip>41522</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+20 1221028158</phone>
      <email>Aymansabry205@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants, Bâtiment Modulaire</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 567771095</phone>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric and Congenital Cardiology and Pulmonology Department; Arnaud De Villeneuve University Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 467336632</phone>
      <email>Hamouda-abassi@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Cardiology Department, Hospital Necker Enfants Malades, APHP, Université Paris Descartes</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex 15</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+33 144494344</phone>
      <email>damien.bonnet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+36 12151220</phone>
      <email>ablonczyl@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36 62545330</phone>
      <email>study.pedia@med.u-szeged.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nirmal Hospital Private Limited</name>
      <address>
        <city>Sūrat</city>
        <state>Gujarat</state>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+91 9979530073</phone>
      <email>drjashvant.patel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health</name>
      <address>
        <city>Mitra, Monjiri</city>
        <state>Kolkata</state>
        <zip>700017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>91 9831075734</phone>
      <email>monjorimr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972 86243589</phone>
      <email>Ayeletpu@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital - Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972 26777511</phone>
      <email>hilay@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+927 35308010</phone>
      <email>oliana.Vazhgovky@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Heart Centre at the American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>11-0236</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+961 1350000</phone>
      <phone_ext>5865</phone_ext>
      <email>fbitar@aub.edu.lb</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de France Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+961 3524424</phone>
      <email>lindadaou@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>34679651335</phone>
      <email>froses@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erciyes University Medical Faculty, Department of Children Hospital</name>
      <address>
        <city>Edirne</city>
        <state>Kayseri</state>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+90 5325570052</phone>
      <email>turkanp@erciyes.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+90 5325263749</phone>
      <email>suleunal@hacettepe.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+90 2124142000</phone>
      <email>zkarakas@istanbul.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Faculty of Medicine Department of Child Health and Diseases</name>
      <address>
        <city>İzmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+90 2323901017</phone>
      <email>Kaan.kavakli@ege.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Izmir-Dr. Behçet Uz. Pediatric Diseases and Surgery Training and Research Hospital- Izmir Dr. Behcet Uz Cocuk Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>İzmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+90 5362013162</phone>
      <email>hasanagin@mynet.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution Dnipropetrovsk Regional Pediatric Clinical Hospital of Dnipropetrovsk Regional Council, State Institution Dnipropetrovsk Medical Academy of MoH of Ukraine</name>
      <address>
        <city>Dnipro</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+380 677671524</phone>
      <email>Vdihtiar2017@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Healthcare Institution Regional Pediatric Clinical Hospital, Kharkiv National Medical University</name>
      <address>
        <city>Kharkiv</city>
        <zip>61093</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+380 506388992</phone>
      <email>margarytagonchar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vynnitsa Regional Children Clinical Hospital Policlinic Dept</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+380432576155</phone>
      <email>olgayablon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 3301288430</phone>
      <email>p.daubeney@rbht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 1162563904</phone>
      <email>frances.bu'lock@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ward 2B, Royal Hospital for Children</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse Administrator</last_name>
      <phone>+44 1414524624</phone>
      <email>alison.spence2@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Lebanon</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2018</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Cardiac disease with potential for thromboembolic complications</keyword>
  <keyword>Prophylactic treatment</keyword>
  <keyword>Anticoagulant drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

